University Hospital of Heidelberg, Department of Radiation Oncology, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Head Neck. 2014 Jan;36(1):22-7. doi: 10.1002/hed.23274. Epub 2013 May 4.
The purpose of this study was to evaluate long-term outcome after radiation therapy (RT) for skull base or head-and-neck chemodectomas.
We treated 39 patients with chemodectomas with RT. Patients were treated with either single dose stereotactic radiosurgery, fractionated stereotactic radiotherapy, or intensity modulated radiotherapy (IMRT), depending on the size and anatomy of the lesion. At primary diagnosis, 16 patients were treated with surgical resection (41%), 4 with interventional embolization (10%), and 19 with primary RT (49%). Single doses of 18 Gy/80% isodose were applied. For fractionated treatments delivered as primary RT, a median total dose of 57.6 Gy was delivered. Five patients were treated with re-irradiation, of which 4 were treated with fractionated regimens; total dose was 28.8 Gy, 30 Gy, 40 Gy, and 56 Gy in 1.8 to 2 Gy single fractions.
Clinical symptoms improved in 18 patients (46%), remained unchanged in 10 patients (26%), and worsening of sequelae was observed in only 1 patient, which was associated with tumor progression. Actuarial local control was 97% at 10 years. Overall survival was 89% at 5 years and 87% at 10 years. Deaths were not disease-related except in 3 patients with tumor progression. No secondary malignancies were observed.
RT has been established as a treatment alternative for patients with glomus tumors. Long-term local control is very high, with good clinical response to treatment.
本研究旨在评估颅底或头颈部化学感受器瘤患者接受放射治疗(RT)后的长期结果。
我们对 39 例化学感受器瘤患者进行了 RT 治疗。根据病变的大小和解剖结构,患者分别接受单次立体定向放射外科手术、分次立体定向放疗或强度调制放疗(IMRT)。在初次诊断时,16 例患者接受了手术切除(41%),4 例患者接受了介入栓塞(10%),19 例患者接受了原发 RT(49%)。单次剂量为 18Gy/80%等剂量线。对于作为原发 RT 给予的分次治疗,中位总剂量为 57.6Gy。5 例患者接受了再放疗,其中 4 例患者接受了分次治疗方案;总剂量分别为 28.8Gy、30Gy、40Gy 和 56Gy,单次剂量为 1.8 至 2Gy。
18 例患者(46%)的临床症状改善,10 例患者(26%)症状无变化,仅 1 例患者出现后遗症恶化,与肿瘤进展有关。10 年时的局部控制率为 97%。5 年和 10 年的总生存率分别为 89%和 87%。除 3 例肿瘤进展患者外,死亡均与疾病无关。未观察到继发性恶性肿瘤。
RT 已成为治疗化学感受器瘤患者的一种治疗选择。长期局部控制率非常高,治疗后临床反应良好。